China Regulatory Express: 12 Months Exclusivity Proposed For First Generics
Plus Draft Guidelines for Gene Therapy
China’s National Medical Products Administration has released several key regulations and proposals designed to encourage first generics through a 12-month market exclusivity proposal and accelerate gene therapy development.
You may also be interested in...
Top executives from three high-flying Chinese biotechs, all of which have gone public on Nasdaq and in Hong Kong, offered lessons learned and looked forward to what’s ahead in a panel session at the recent JPM conference.
Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.